close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

56.42 +5.86 (+11.59%)
Streaming Delayed Price Updated: 12:37 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗
On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 ↗
The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S. 
Via Stocktwits
Topics Artificial Intelligence
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
TG Therapeutics TGTX Q3 2025 Earnings Transcript ↗
TG Therapeutics TGTX Q3 2025 Earnings Transcript 
Via The Motley Fool
TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For TG Therapeutics ↗
 
Via Benzinga
TG Therapeutics Board Authorizes New $100M Share Repurchase Program ↗
Via Stocktwits
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics. 
Via Investor's Business Daily
News headline image
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million ↗
Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
What's Next: TG Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
News headline image
Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat ↗
TG Therapeutics stock rose early Monday on better-than-expected earnings. 
Via Investor's Business Daily
Topics Earnings
News headline image
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup ↗
TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch. 
Via Chartmill
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback ↗
TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects. 
Via Benzinga
News headline image
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug ↗
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. 
Via Stocktwits
Topics Earnings
News headline image
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗
 
Via Benzinga
News headline image
Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide ↗
TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth. 
Via Benzinga
News headline image
TG Therapeutics Q2 Revenue Up 91% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook ↗
The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche. 
Via Investor's Business Daily
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance ↗
TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook. 
Via Chartmill
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup ↗
TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,... 
Via Chartmill
News headline image
TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template ↗
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal... 
Via Chartmill
News headline image
Cramer Backs This Mining Giant After $1.6B Bet ↗
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.